ARTEMIS: 192-week efficacy and safety of once-daily darunavir/ritonavir (DRV/r) vs lopinavir/r (LPV/r) in treatment-naïve HIV-1-infected adults

Documenti analoghi

• Pharmacokinetic (PK) and pharmacodynamic analyses of once- and twice-daily darunavir/ritonavir (DRV/r) in the ODIN trial
  di: Sekar, V, et al.
  Pubblicazione: (2010)
• Health-related quality of life (HRQoL) assessment with once- and twice-daily darunavir/ritonavir (DRV/r) in the ODIN trial
  di: Spinosa-Guzman, S, et al.
  Pubblicazione: (2010)
• Influence of demographic and disease parameters on virological response to once- vs twice-daily darunavir/ritonavir (DRV/r) at week 48 in ODIN
  di: Sension, M, et al.
  Pubblicazione: (2010)
• Outcomes related to 4864 pregnancies with exposure to lopinavir/ritonavir (LPV/r)
  di: Tookey, Pat, et al.
  Pubblicazione: (2014)
• Effectiveness and durability of darunavir/ritonavir (DRV/r) in DRV/r-experienced HIV-1-infected patients in routine clinical practice
  di: Antinori, Andrea, et al.
  Pubblicazione: (2014)